APA (7th ed.) Citation

NE, K., K, Q., TA, G., CH, M., S, C., MM, P., . . . RD, C. (2024). Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial. JAMA oncology, 10(7), 961. https://doi.org/10.1001/jamaoncol.2024.0967

Chicago Style (17th ed.) Citation

NE, Kopmar, et al. "Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial." JAMA Oncology 10, no. 7 (2024): 961. https://doi.org/10.1001/jamaoncol.2024.0967.

MLA (9th ed.) Citation

NE, Kopmar, et al. "Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial." JAMA Oncology, vol. 10, no. 7, 2024, p. 961, https://doi.org/10.1001/jamaoncol.2024.0967.